SCHEMBL3241960

SCHEMBL3241960

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC4CN5CCC4CC5)cc3c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
POLB P06746 8/20 0.39
HSD17B10 Q99714 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP2C9 P11712 1/20 0.39
PARG Q86W56 1/20 0.38
MAPT P10636 6/20 0.38
TP53 P04637 4/20 0.38
LMNA P02545 2/20 0.38
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
HPGD P15428 3/20 0.37
ALDH1A1 P00352 2/20 0.37
ALOX15 P16050 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
USP2 O75604 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248324 0.88 PARG (0.42) KDM4EPOLBHSD17B10MEN1KMT2A
SCHEMBL3247352 0.88 KDM4E (0.40) KDM4EPOLBHSD17B10MEN1KMT2A
SCHEMBL3250602 0.86 PARG (0.50) KDM4EPOLBHSD17B10MEN1KMT2A
SCHEMBL3247256 0.84 TDP1 (0.53) POLBHSD17B10PARGMAPTTP53
SCHEMBL3250480 0.84 TDP1 (0.53) POLBHSD17B10PARGMAPTTP53
SCHEMBL3254905 0.83 PARG (0.45) POLBHSD17B10MEN1KMT2APARG
SCHEMBL3248891 0.82 PARG (0.41) KDM4EPOLBHSD17B10MEN1KMT2A
SCHEMBL3248963 0.81 TAS2R14 (0.44) KDM4EHSD17B10MEN1KMT2AMAPT
SCHEMBL4161656 0.81 PARG (0.39) KDM4EHSD17B10MEN1KMT2APARG
SCHEMBL3242035 0.80 GABRA1 (0.45) KDM4EPOLBHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885POLB 1007/4885HSD17B10 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.